Abviva to receive patent for its new Mammastatin technology

[News]

Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2.267.095 within 12 weeks

More... (http://www.news-medical.net/news/20100727/Abviva-to-receive-patent-for-its-new-Mammastatin-technology.aspx)